SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-24-028704
Filing Date
2024-02-28
Accepted
2024-02-28 16:05:21
Documents
15
Period of Report
2024-02-28
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm247491d1_8k.htm   iXBRL 8-K 26361
2 EXHIBIT 99.1 tm247491d1_ex99-1.htm EX-99.1 77679
  Complete submission text file 0001104659-24-028704.txt   289833

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA iova-20240228.xsd EX-101.SCH 3003
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE iova-20240228_lab.xml EX-101.LAB 34240
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE iova-20240228_pre.xml EX-101.PRE 22351
16 EXTRACTED XBRL INSTANCE DOCUMENT tm247491d1_8k_htm.xml XML 3633
Mailing Address 825 INDUSTRIAL ROAD 4TH FLOOR SAN CARLOS CA 94070
Business Address 825 INDUSTRIAL ROAD 4TH FLOOR SAN CARLOS CA 94070 6502607120
IOVANCE BIOTHERAPEUTICS, INC. (Filer) CIK: 0001425205 (see all company filings)

IRS No.: 753254381 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36860 | Film No.: 24695201
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)